Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
The sustained cell proliferation resulting from dysregulation of the cell cycle and activation of cyclin-dependent kinases (CDKs) is a hallmark of cancer. The inhibition of CDKs is a highly promising and attractive strategy for the development of anticancer drugs. In particular, third-generation CDK...
Main Authors: | Kai Yuan, Xiao Wang, Haojie Dong, Wenjian Min, Haiping Hao, Peng Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Acta Pharmaceutica Sinica B |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383520305839 |
Similar Items
-
Cell cycle regulation and anticancer drug discovery
by: Jingwen Bai, et al.
Published: (2017-08-01) -
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01) -
Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia
by: Patrizia Porazzi, et al.
Published: (2021-08-01) -
Pax6 Lengthens G1 Phase and Decreases Oscillating Cdk6 Levels in Murine Embryonic Cortical Progenitors
by: Da Mi, et al.
Published: (2018-11-01) -
Inhibition chimique des Cdk : mécanisme biochimiques et conséquences cellulaires
by: Cot, Emilie
Published: (2010)